AbbVie Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
Why AbbVie Stock Slumped Today
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and Rinvoq, Pipeline Advances
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
Pre-Market Trading Up in Final Session of the Week
AbbVie Q2 Earnings Call Highlights
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
AbbVie Reports Second-Quarter 2026 Financial Results
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
JUVÉDERM® Day Returns to U.S. on August 19
AbbVie Inc. $ABBV Position Increased by Arkadios Wealth Advisors
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now